Payment overview · 2025
General Payments
$929.21
51 reported records · 13 companies
Healthcare provider profile · identity verified
Jennifer Thompson-Davis, MD
Allopathic & Osteopathic Physicians|Family Medicine · NEW ALBANY, MS · NPI 1639350150
Verified facts
What the public records show
CMS Open Payments records show Jennifer Thompson-Davis, MD received $929.21 in general payments during 2025 across 51 reported records.
AstraZeneca Pharmaceuticals LP accounted for 19.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 222 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $182.11 | 19.6% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $152.66 | 16.4% | 13 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $143.18 | 15.4% | 10 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $82.86 | 8.9% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $81.37 | 8.8% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $78.71 | 8.5% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $50.95 | 5.5% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $50.46 | 5.4% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $43.02 | 4.6% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.33 | 1.9% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.23 | 1.8% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $15.65 | 1.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.68 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $929.21 | 51 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $149.02 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $143.18 | 10 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $133.32 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $117.81 | 10 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $107.74 | 9 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $104.62 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $81.37 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $78.71 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $66.00 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $50.95 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $50.95 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $43.02 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $34.85 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $33.09 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.33 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $16.23 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $15.65 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 222 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 99 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 77 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 141 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 58 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
36 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
99 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
58 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
70 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
77 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
51 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
141 | 32 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
222 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 550 | 95 |
| Levothyroxine Sodium | Levothyroxine Sodium | 518 | 65 |
| Atorvastatin Calcium | Atorvastatin Calcium | 514 | 98 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 453 | 91 |
| Furosemide | Furosemide | 441 | 68 |
| Pantoprazole Sodium | Pantoprazole Sodium | 393 | 63 |
| Duloxetine Hcl | Duloxetine Hcl | 375 | 30 |
| Omeprazole | Omeprazole | 374 | 70 |
| Amlodipine Besylate | Amlodipine Besylate | 350 | 72 |
| Potassium Chloride | Potassium Chloride | 349 | 54 |
| Famotidine | Famotidine | 310 | 25 |
| Lisinopril | Lisinopril | 289 | 69 |
| Metoprolol Succinate | Metoprolol Succinate | 281 | 61 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 273 | 63 |
| Trazodone Hcl | Trazodone Hcl | 269 | 32 |
| Losartan Potassium | Losartan Potassium | 237 | 54 |
| Eliquis | Apixaban | 222 | 19 |
| Carvedilol | Carvedilol | 220 | 33 |
| Meloxicam | Meloxicam | 219 | 52 |
| Mirtazapine | Mirtazapine | 214 | 33 |
| Buspirone Hcl | Buspirone Hcl | 193 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 183 | 17 |
| Allopurinol | Allopurinol | 169 | 22 |
| Simvastatin | Simvastatin | 167 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 165 | 53 |
| Metformin Hcl | Metformin Hcl | 162 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 161 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 157 | 33 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 156 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 154 | 23 |
| Montelukast Sodium | Montelukast Sodium | 153 | 42 |
| Tizanidine Hcl | Tizanidine Hcl | 142 | 50 |
| Ozempic | Semaglutide | 141 | 32 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 132 | 21 |
| Ondansetron Odt | Ondansetron | 130 | 55 |
| Donepezil Hcl | Donepezil Hcl | 128 | 20 |
| Tramadol Hcl | Tramadol Hcl | 128 | 34 |
| Bupropion Xl | Bupropion Hcl | 123 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 123 | 35 |
| Clonazepam | Clonazepam | 121 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 116 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 112 | 16 |
| Levetiracetam | Levetiracetam | 110 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 109 | 16 |
| Pregabalin | Pregabalin | 108 | 24 |
| Prednisone | Prednisone | 105 | 79 |
| Alprazolam | Alprazolam | 101 | 25 |
| Farxiga | Dapagliflozin Propanediol | 99 | 15 |
| Memantine Hcl | Memantine Hcl | 97 | 11 |
| Metformin Hcl Er | Metformin Hcl | 97 | 21 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 95 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 95 | suppressed |
| Lorazepam | Lorazepam | 91 | 16 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 90 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 90 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 87 | 24 |
| Olanzapine | Olanzapine | 87 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 85 | suppressed |
| Methocarbamol | Methocarbamol | 85 | 21 |
| Topiramate | Topiramate | 85 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 84 | 33 |
| Meclizine Hcl | Meclizine Hcl | 80 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 79 | 12 |
| Fluconazole | Fluconazole | 78 | 34 |
| Mounjaro | Tirzepatide | 77 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 76 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 74 | 21 |
| Baclofen | Baclofen | 72 | 12 |
| Jardiance | Empagliflozin | 70 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 68 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 68 | 12 |
| Diazepam | Diazepam | 67 | 14 |
| Promethazine Hcl | Promethazine Hcl | 66 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 65 | 21 |
| Sertraline Hcl | Sertraline Hcl | 65 | 17 |
| Spironolactone | Spironolactone | 65 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 64 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 64 | suppressed |
| Azithromycin | Azithromycin | 63 | 54 |
| Primidone | Primidone | 63 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 61 | 19 |
| Glyxambi | Empagliflozin/Linagliptin | 60 | suppressed |
| Januvia | Sitagliptin Phosphate | 59 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 59 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 58 | 13 |
| Propranolol Hcl | Propranolol Hcl | 56 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 55 | suppressed |
| Ibuprofen | Ibuprofen | 54 | 20 |
| Digoxin | Digoxin | 53 | suppressed |
| Dutasteride | Dutasteride | 53 | suppressed |
| Fenofibrate | Fenofibrate | 53 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 53 | suppressed |
| Ramipril | Ramipril | 52 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 52 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 52 | 11 |
| Trulicity | Dulaglutide | 51 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 50 | 43 |
| Cefdinir | Cefdinir | 49 | 39 |
| Diclofenac Sodium | Diclofenac Sodium | 49 | 20 |
| Diltiazem 24hr Er | Diltiazem Hcl | 47 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 45 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 45 | 12 |
| Oxcarbazepine | Oxcarbazepine | 45 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 45 | suppressed |
| Naproxen | Naproxen | 44 | suppressed |
| Eszopiclone | Eszopiclone | 43 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 43 | 15 |
| Xarelto | Rivaroxaban | 42 | suppressed |
| Ezetimibe | Ezetimibe | 41 | 11 |
| Nystatin | Nystatin | 40 | 23 |
| Estradiol | Estradiol | 39 | suppressed |
| Nitroglycerin | Nitroglycerin | 39 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 38 | 33 |
| Linzess | Linaclotide | 36 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 36 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 32 |
| Megestrol Acetate | Megestrol Acetate | 35 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 33 | 11 |
| Methylprednisolone | Methylprednisolone | 33 | 28 |
| Movantik | Naloxegol Oxalate | 33 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 32 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | suppressed |
| Chlorthalidone | Chlorthalidone | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | suppressed |
| Levofloxacin | Levofloxacin | 30 | 21 |
| Verapamil Er | Verapamil Hcl | 30 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 28 | suppressed |
| Cephalexin | Cephalexin | 27 | 16 |
| Temazepam | Temazepam | 27 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 27 | 14 |
| Cilostazol | Cilostazol | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 26 | suppressed |
| Risperidone | Risperidone | 26 | suppressed |
| Celecoxib | Celecoxib | 25 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 17 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 19 |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 20 | suppressed |
| Latanoprost | Latanoprost | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 20 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 20 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Methotrexate | Methotrexate Sodium | 19 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Roflumilast | Roflumilast | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 12 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 13 |
| Ursodiol | Ursodiol | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Nystop | Nystatin | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
| Savella | Milnacipran Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $929.21 · 51 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, Korlym, MOUNJARO, NEXLETOL, NURTEC ODT, Ozempic, REXULTI, Rybelsus, TRELEGY ELLIPTA, VRAYLAR, Wegovy, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error